

1 **Middle meningeal artery embolization for subdural hematoma:**  
2 **protocol for a systematic review and meta-analysis of randomized**  
3 **controlled trials**

4 Alick P Wang\*<sup>1</sup> MD MSc, Husain Shakil<sup>2</sup> MD MSc, Brian J Drake<sup>1</sup> MBBCh MPH FRCSC

5 1. Division of Neurosurgery, Department of Surgery, University of Ottawa

6 2. Division of Neurosurgery, Department of Surgery, University of Toronto

7 \* Corresponding author:

8 Alick P Wang, MD MSc

9 The Ottawa Hospital, Civic Campus

10 1053 Carling Ave, Ottawa Ontario, Canada, K1Y4E9

11 alickwang@gmail.com

## 12 **Abstract**

13 (178 words)

14 Background: Middle meningeal artery embolization is an emerging neuroendovascular therapy  
15 for chronic subdural hematoma. Recently, a number of randomized control trials have been  
16 conducted to assess the efficacy of middle meningeal artery embolization to reduce the  
17 recurrence or progression of chronic subdural hematoma.

18 Methods: A systematic review will be conducted following the Preferred Reporting Items for  
19 Systematic Reviews and Meta-Analysis (PRISMA) guidelines. The authors will systematically  
20 search MEDLINE, EMBASE, Cochrane, and ClinicalTrials.gov (National Library of Medicine)  
21 for randomized control trials evaluating middle meningeal artery embolization for chronic  
22 subdural hematoma. A meta-analysis will be undertaken to compare patients undergoing middle  
23 meningeal artery embolization and standard care compared to standard care alone; primary  
24 effectiveness endpoints will be symptomatic recurrence, radiographic re-accumulation, or  
25 reoperation; secondary safety endpoints will be new disabling stroke, myocardial infarction, or  
26 death within 30 days.

27 Discussion: This proposed systematic review and meta-analysis will synthesize and appraise  
28 available data regarding middle meningeal artery embolization, a novel neurointerventional  
29 therapy. Findings will help clinicians, patients, administrators, policy makers to determine the  
30 role of this new treatment and its potential benefits.

31 Systematic review registration: PROSPERO #CRD42024512049

## 32 **Keywords**

33 Meta-analysis; Middle meningeal artery embolization; Randomized control trial; Subdural  
34 hematoma.

## 35 **Background**

36 Chronic subdural hematoma (CSDH) is a common condition, with an incidence of up to 20.6 per  
37 100,000 person-years<sup>1</sup>. It disproportionately affects elderly populations and is often caused by  
38 minor trauma. It can cause symptoms ranging from headaches to confusion, decreased level of  
39 consciousness, weakness, aphasia, or seizures.

40 Depending on the volume, local mass effect, and symptoms, chronic SDH has been treated either  
41 surgically (burr hole evacuation, craniotomy, or subdural drainage ports) or conservatively  
42 (medical therapy or observation/serial imaging). Conservatively managed SDH can progress in  
43 up to 34% of cases<sup>2</sup>. After surgical evacuation, recurrence rates have been estimated between 10-  
44 20%<sup>3</sup>.

45 Recently, endovascular embolization of the middle meningeal artery (EMMA) has become an  
46 emerging therapy for CSDH<sup>4</sup>. While EMMA was initially used in patients who were at high risk  
47 of recurrence, the indications have recently widened to all patients with CSDH. Although  
48 EMMA does not immediately remove the SDH or its mass effect, it is hypothesized to  
49 devascularize the subdural membrane and prevent recurrence or progression.

50 EMMA has been used in cases of small, asymptomatic SDH not requiring surgery<sup>5</sup> as well as in  
51 cases of SDH requiring surgical evacuation<sup>6</sup>. A recent systematic review found that EMMA  
52 reduced the risk of recurrence from 23.5% to 3.5% (RR 0.17)<sup>7</sup>. However, at the time of  
53 publication, there had not been any prospectively conducted randomized control trials (RCTs).

54 Recently, a number of multi-centre RCTs have been conducted to evaluate the efficacy of  
55 EMMA for reducing recurrence or progression in CSDH. A meta-analysis of these trials has yet  
56 to be performed.

## 57 **Methods/Design**

58 This protocol outlines the design and conduct of our intended systematic review and meta-  
59 analysis in compliance with the guideline Preferred Reporting Items for Systematic Reviews and  
60 Meta-analyses (PRISMA). The protocol has been submitted to the PROSPERO database and  
61 assigned the unique identifier #CRD42024512049. This study was exempt from institutional  
62 research ethics board review under article 1B of the University of Toronto policy on Human  
63 Research Exempt from REB Review ([https://research.utoronto.ca/ethics-human-](https://research.utoronto.ca/ethics-human-research/activities-exempt-human-ethics-review)  
64 [research/activities-exempt-human-ethics-review](https://research.utoronto.ca/ethics-human-research/activities-exempt-human-ethics-review))

### 65 *Study Aim*

66 We aim to conduct a meta-analysis of available data from RCTs comparing the efficacy of  
67 EMMA in addition to standard of care to standard of care alone. The primary efficacy endpoints  
68 will be the likelihood of SDH recurrence, re-accumulation, or re-operation at 90 days, and 180  
69 days.

### 70 *Data Sources and Study Eligibility*

71 Two authors (APW, HS) will independently search citations from MEDLINE, EMBASE,  
72 Cochrane, and ClinicalTrials.gov (National Library of Medicine) without language restriction  
73 (see Appendix 1 for search strategy). We will include randomized control trials studying adult  
74 patients ( $\geq 18$  years of age) with radiographic diagnosis of chronic or subacute SDH, with at  
75 least 10 patients, and at least 90 days of follow-up.

### 76 *Treatment Groups*

77 The intervention group of interest will be the use of EMMA in addition to standard of care. The  
78 control group will be treatment with standard of care alone. Standard of care will include  
79 observation, medical therapy, burr hole, mini-craniotomy, craniotomy, and subdural evacuation  
80 port system.

### 81 *Outcomes*

82 The primary effectiveness endpoints for this study will be symptomatic recurrence, radiographic  
83 re-accumulation, or reoperation at 90, and 180 days. We will also aim to assess a secondary  
84 safety endpoint of new major disabling stroke, myocardial infarction, or death from any  
85 neurological cause within 30 days.

### 86 *Data Extraction*

87 Spreadsheet software will be used by two authors (APW, HS) to extract study design,  
88 inclusion/exclusion criteria, randomization characteristics, patient population, primary and  
89 secondary outcome measures, and sources of bias, and covariates. Covariates will include age,  
90 standard treatment approach used, presence of symptoms, type of embolization material, and use  
91 of general anesthetic for EMMA procedure.

### 92 *Risk of Bias/Quality Assessment*

93 Two reviewers (APW, HS) will independently perform quality assessment of included studies.  
94 The Cochrane ROB 2 tool<sup>8</sup> will be applied to assess the risk of bias related to the randomization  
95 process, deviations from intended interventions, missing data, measurement of the outcome, and  
96 selection of the reported results. We judged trials with more than 2 high-risk components as  
97 having a moderate overall risk of bias, and trials with more than 4 high-risk components as  
98 having a high overall risk of bias. The GRADE approach<sup>9</sup> will be used for appraisal of the  
99 quality of evidence.

## 100 *Statistical Analysis*

101 All analyses will be conducted in R version 4.3.1 with a priori specified significance level of  $p <$   
102 0.05 for two-tailed tests. We will follow an intention-to-treat approach in assigning treatment  
103 groups.

104 The odds ratio (OR) of SDH recurrence and associated 95% confidence intervals (CI) for  
105 EMMA with standard therapy compared to standard therapy alone will be estimated for each  
106 study using logistic regression.

107 Heterogeneity in the treatment effect across trials will be investigated by the Cochran Q test and  
108 measured by the  $I^2$  statistic, with  $I^2$  values exceeding 25%, 50%, and 75% representing low,  
109 moderate, and high heterogeneity, respectively<sup>10</sup>. Treatment effect estimates will be pooled using  
110 a fixed effect Mantel-Haenszel method if heterogeneity is found to be low heterogeneity. A  
111 DerSimonian and Laird random-effects model<sup>11</sup> will be used if moderate-high heterogeneity is  
112 found.

113 Publication bias will be assessed using Funnel plots and Egger's test<sup>12</sup>. We will further  
114 investigate the effect of covariates including age, standard treatment approach, presence of  
115 symptoms, history of prior subdural hematoma, use of general anesthetic, and type of  
116 embolization material used. We will assess missingness of covariates and outcomes. Based on  
117 data availability, we will conduct subgroup analyses based on presence of symptoms, type of  
118 standard management (e.g. conservative, medical, burr-hole, and craniotomy), older patients, or  
119 patients with prior subdural hematoma. We will not impute data on outcomes or treatment  
120 assignment, and will only analyze available data for these variables. For study covariates, we  
121 will impute data found to be missing completely at random, or missing at random there is less  
122 than 20% missingness.

123 **Discussion**

124 This proposed systematic review and meta-analysis will address an important knowledge gap  
125 regarding EMMA, a novel neurointerventional therapy.

126 While several studies have evaluated the safety and benefit of EMMA<sup>3</sup>, up until recently there  
127 had not been any prospective RCTs conducted to evaluate its efficacy. Recently, a number of  
128 multi-centre RCTs have been completed and early results have been presented at the  
129 International Stroke Conference 2024.

130 A meta-analysis of RCTs will help clinicians, patients, administrators, policy makers to  
131 determine the role of this new treatment and its potential benefits.

132 **List of abbreviations**

133 CSDH - chronic subdural hematoma

134 EMMA - embolization of the middle meningeal artery

135 MMA - middle meningeal artery

136 PRISMA - Preferred Reporting Items for Systematic Reviews and Meta-analyses

137 RCT - randomized control trial

138 SDH - subdural hematoma

139 **Declarations**

140 *Ethics approval*

141 No ethics approval required for systematic review.

142 *Availability of data and materials*

143 All data will be extracted from publicly available publications. Extracted data will be made  
144 available upon reasonable request.

145 *Competing interests*

146 No competing interests to declare.

147 *Funding*

148 No funding to declare.

149 *Authors' contributions*

150 APW, HS, and BJD study conception. APW and HS protocol design and drafting.



## 151 **References**

- 152 1. Feghali, J., Yang, W. & Huang, J. Updates in Chronic Subdural Hematoma: Epidemiology,  
153 Etiology, Pathogenesis, Treatment, and Outcome. *World Neurosurg* 141, 339–345 (2020).
- 154 2. Foppen, M., Bandral, H. V., Slot, K.-A. M., Vandertop, W. P. & Verbaan, D. Success of  
155 conservative therapy for chronic subdural hematoma patients: a systematic review.  
156 *Frontiers in Neurology* 14, (2023).
- 157 3. Almenawer, S. A. et al. Chronic subdural hematoma management: a systematic review and  
158 meta-analysis of 34,829 patients. *Ann Surg* 259, 449–457 (2014).
- 159 4. Rudy, R. F., Catapano, J. S., Jadhav, A. P., Albuquerque, F. C. & Ducruet, A. F. Middle  
160 Meningeal Artery Embolization to Treat Chronic Subdural Hematoma. *Stroke: Vascular  
161 and Interventional Neurology* 3, e000490 (2023).
- 162 5. Rojas-Villabona, A. et al. A systematic review of middle meningeal artery embolization for  
163 minimally symptomatic chronic subdural haematomas that do not require immediate  
164 evacuation. *Brain and Spine* 3, 102672 (2023).
- 165 6. Lam, A. et al. The efficacy of postoperative middle meningeal artery embolization on  
166 chronic subdural hematoma - A multicentered randomized controlled trial. *Surg Neurol Int*  
167 14, 168 (2023).
- 168 7. Dian, J., Linton, J. & Shankar, J. J. Risk of recurrence of subdural hematoma after EMMA  
169 vs surgical drainage – Systematic review and meta-analysis. *Interv Neuroradiol* 27, 577–  
170 583 (2021).
- 171 8. Sterne, J. A. C. et al. RoB 2: a revised tool for assessing risk of bias in randomised trials.  
172 *BMJ* 366, 14898 (2019).
- 173 9. Guyatt, G. H. et al. GRADE: an emerging consensus on rating quality of evidence and  
174 strength of recommendations. *BMJ* 336, 924–926 (2008).
- 175 10. Higgins, J. P. T., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency  
176 in meta-analyses. *BMJ* 327, 557–560 (2003).
- 177 11. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. *Control Clin Trials* 7, 177–  
178 188 (1986).
- 179 12. Egger, M., Davey Smith, G., Schneider, M. & Minder, C. Bias in meta-analysis detected by  
180 a simple, graphical test. *BMJ* 315, 629–634 (1997).

181 **Appendix 1:**

182 *Search Strategy*

183 The following search strategy will be employed for the MEDLINE database using the OVID  
184 interface.

- 185 1. exp Hematoma, Subdural/
- 186 2. exp Embolization Therapeutic/
- 187 3. exp Meningeal Arteries/
- 188 4. exp Endovascular Procedures/
- 189 5. Exp Clinical Trial/
- 190 6. 2 or 3 or 4
- 191 7. 1 and 5 and 6